ATHE · Alterity Therapeutics Ltd · Insider Trading

$2.10 -0.22 (-9.31%) At close · Nov 12 Q2 2021 earnings call transcript

Market Cap

$40.00M

19.09M

Volume · Nov 12 71.75K Avg daily vol (3M) 86.25K

Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.

Query insider transactions through the insider trading API or MCP →

Insider Sentiment Score

Peer-relative 0–100 rank of how aggressively insiders accumulated over the trailing 90 days. See the full ranking.

Net buyers

Net shares bought

0.25%

Net buy value

+$23,810

Date	Insider	Role	Type	Security	Shares	Price	Value	After
2026-08-31	Marks Peter Ashley	Director	Buy↑	Ordinary shares (I)	47,620	$0.50	$23,810	191,340
2026-08-31	Marks Peter Ashley	Director	Buy↓	Listed option exp 31 Aug 2026 (I)	47,620	$0.50	$23,810	0
2026-08-31	Stamler David Allen	Director, Chief Executive Officer	Buy↓	Listed option exp 31 Aug 2026	47,620	$0.50	$23,810	0
2026-06-15	Gozlan Lawrence Bernard	Director	Award↑	Listed option exp 15 Jun 2031 (I)	1,000,000	—	—	1,000,000
2026-06-15	Babarczy Julian Michael	Director	Award↑	Unlisted option exp 15 Jun 2031 (I)	2,000,000	—	—	2,000,000

Legend Buy — open-market purchase Sell — open-market sale ↑ Shares acquired ↓ Shares disposed (gift, conversion, tax…)

Showing 1–5 of 5 transactions

Key facts CIK 1131343 CUSIP 02155X205 13F (30d) 14 filings 14 filers Visit website Investor relations